Can Interim F-18-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy? A Preliminary Study in 15 Patients

Mayerhoefer Marius E.; Karanikas Georgios; Kletter Kurt; Kiesewetter Barbara; Weber Michael; Rausch Ivo; Pones Matthias; Simonitsch-Klupp Ingrid; Muellauer Leonhard; Dolak Werner; Lukas Julius; Raderer Markus

首页> 外文期刊>Clinical nuclear medicine >Can Interim F-18-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy? A Preliminary Study in 15 Patients

【24h】

Can Interim F-18-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy? A Preliminary Study in 15 Patients

机译：临时F-18-FDG PET或弥散加权MRI能否预测以利妥昔单抗为基础的治疗后FDG-Avid MALT淋巴瘤的治疗结局？对15例患者的初步研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To determine whether interim F-18-FDG PET or interim diffusion-weighted magnetic resonance imaging (DWI) can predict the end-of-treatment (EOT) outcome after immunotherapy in patients with FDG-avid extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT).

机译：目的：确定FDG-avid结外边缘区B细胞淋巴瘤患者接受免疫治疗后，中期F-18-FDG PET或中期弥散加权磁共振成像（DWI）是否可以预测治疗结束（EOT）结果粘膜相关淋巴组织（MALT）的表达。

著录项

来源
《Clinical nuclear medicine》 |2016年第11期|共7页
作者
Mayerhoefer Marius E.; Karanikas Georgios; Kletter Kurt; Kiesewetter Barbara; Weber Michael; Rausch Ivo; Pones Matthias; Simonitsch-Klupp Ingrid; Muellauer Leonhard; Dolak Werner; Lukas Julius; Raderer Markus;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词
lymphoma; F-18-FDG; PET; magnetic resonance imaging;

机译：淋巴瘤;F-18-FDG;PET;磁共振成像;

相似文献

外文文献
中文文献
专利

1. Can Interim F-18-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy? A Preliminary Study in 15 Patients [J] . Mayerhoefer Marius E., Karanikas Georgios, Kletter Kurt, Clinical nuclear medicine . 2016,第11期

机译：临时F-18-FDG PET或弥散加权MRI能否预测以利妥昔单抗为基础的治疗后FDG-Avid MALT淋巴瘤的治疗结局？对15例患者的初步研究
2. Interobserver Agreement of Interim and End-of-Treatment F-18-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials [J] . Burggraaff Coreline N., Cornelisse Alexander C., Hoekstra Otto S., The Journal of Nuclear Medicine . 2018,第12期

机译：Interobserver临时和治疗结束F-18-FDG PET / CT在弥漫性大B细胞淋巴瘤中的临床协议：对临床实践和试验的影响
3. Prognostic value of baseline, interim and end-of-treatment F-18-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis [J] . Wang Hongxi, Shen Guohua, Jiang Chong, Journal of land use science . 2018,第1a3期

机译：基线的预后价值，临时和治疗结束F-18-FDG PET / CT参数在外侧天然杀伤/ T细胞淋巴瘤：荟萃分析
4. Prognostic value of interim 18F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis [O] . Danxia Zhu, Xiao-Li Xu, Cheng Fang, 2015

机译：中期18F-FDG-PET在以利妥昔单抗为基础的免疫化学疗法治疗弥漫性大B细胞淋巴瘤中的预后价值：系统评价和荟萃分析
5. 1 The Interim 18-FDG-PET/CT Failed to Predict the Outcome in Diffuse Large B-Cell Lymphoma Patients Treated at the Diagnosis with Rituximab-CHOP Short title: Interim PET does not predict the outcome in DLBCL [O] . Patrizia Pregno, Marilena Bellò, Barbara Botto, 2016

机译：1临时18-FDG-pET / CT未能预测利妥昔单抗-CHOp诊断治疗弥漫性大B细胞淋巴瘤患者的结果简称：临时pET不能预测DLBCL的结果

Can Interim F-18-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy? A Preliminary Study in 15 Patients

摘要

著录项

相似文献

相关主题

期刊订阅